spironolactone has been researched along with Angiogenesis, Pathologic in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone is an aldosterone receptor antagonist used to control fluid overload in cirrhotic patients although recent studies suggest that it also inhibits angiogenesis." | 5.42 | The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. ( Chang, CC; Ho, HL; Hsin, IF; Hsu, SJ; Huang, HC; Huo, TI; Lee, FY; Lee, SD; Lin, HC; Wang, SS, 2015) |
| "Spironolactone is an aldosterone receptor antagonist used to control fluid overload in cirrhotic patients although recent studies suggest that it also inhibits angiogenesis." | 1.42 | The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. ( Chang, CC; Ho, HL; Hsin, IF; Hsu, SJ; Huang, HC; Huo, TI; Lee, FY; Lee, SD; Lin, HC; Wang, SS, 2015) |
| "Spironolactone can inhibit hepatic sinusoid angiogenesis in rats with BDL-induced hepatic fibrosis by inhibiting the expression of VEGF-A." | 1.38 | [Spironolactone inhibits hepatic sinusoid angiogenesis in rats with hepatic fibrosis]. ( Cai, S; Li, X; Li, Y; Ning, Z; Zhang, L; Zhang, W, 2012) |
| "Spironolactone has recently been shown to have suppressive effects on several immunoactive and proinflammatory cytokines." | 1.34 | Effects of spironolactone on corneal allograft survival in the rat. ( Gong, N; Mergler, S; Otasevic, L; Pleyer, U; Ritter, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, SJ | 1 |
| Wang, SS | 1 |
| Huo, TI | 1 |
| Lee, FY | 1 |
| Huang, HC | 1 |
| Chang, CC | 1 |
| Hsin, IF | 1 |
| Ho, HL | 1 |
| Lin, HC | 1 |
| Lee, SD | 1 |
| Wilkinson-Berka, JL | 1 |
| Tan, G | 1 |
| Jaworski, K | 1 |
| Harbig, J | 1 |
| Miller, AG | 1 |
| Brandt, CJ | 1 |
| Kammer, D | 1 |
| Fiebeler, A | 1 |
| Klinge, U | 1 |
| Li, X | 1 |
| Cai, S | 1 |
| Ning, Z | 1 |
| Li, Y | 1 |
| Zhang, W | 1 |
| Zhang, L | 1 |
| Otasevic, L | 1 |
| Gong, N | 1 |
| Ritter, T | 1 |
| Mergler, S | 1 |
| Pleyer, U | 1 |
| Klauber, N | 1 |
| Browne, F | 1 |
| Anand-Apte, B | 1 |
| D'Amato, RJ | 1 |
6 other studies available for spironolactone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats.
Topics: Ammonia; Animals; Bile Ducts; Body Weight; Hemodynamics; Hepatic Encephalopathy; Kidney; Ligation; L | 2015 |
Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Topics: Aldosterone; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cell | 2009 |
Beneficial effects of hydrocortisone or spironolactone coating on foreign body response to mesh biomaterial in a mouse model.
Topics: Animals; Coated Materials, Biocompatible; Collagen; Disease Models, Animal; Foreign-Body Reaction; G | 2011 |
[Spironolactone inhibits hepatic sinusoid angiogenesis in rats with hepatic fibrosis].
Topics: Animals; Hepatic Veins; Liver Cirrhosis, Experimental; Male; Neovascularization, Pathologic; Rats; R | 2012 |
Effects of spironolactone on corneal allograft survival in the rat.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antibody Formation; Cornea; Corneal Transpl | 2007 |
New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo.
Topics: Animals; Cattle; Cell Division; Cells, Cultured; Chemotaxis; Chick Embryo; Cornea; Endothelial Growt | 1996 |